News

Tyvaso boosts lung function in IPF trial, per top-line data

The inhalation therapy Tyvaso (treprostinil) significantly improved a measure of lung function for people with idiopathic pulmonary fibrosis (IPF) in a Phase 3 clinical trial. The top-line result means that the Phase 3 TETON 2 clinical trial (NCT05255991) has met its main goal. Tyvaso’s developer, United…

UK approves Phase 2 trial for IPF therapy candidate LTI-03

Rein Therapeutics is working with clinical sites to begin recruiting patients in the U.K. for its Phase 2 trial of LTI-03, a therapy candidate for idiopathic pulmonary fibrosis (IPF), after receiving approval from the country’s Medicines and Healthcare Products Regulatory Agency (MHRA). “This MHRA approval marks an important…

KL-6 protein levels may predict symptom worsening in IPF: Study

Consistently tracking the levels of Krebs von den Lungen-6 (KL-6), a protein that can indicate lung inflammation or damage, may help predict acute exacerbations in people with idiopathic pulmonary fibrosis (IPF) and other types of fibrotic interstitial lung diseases (ILDs), a study reports. Findings indicated that KL-6 levels tended…

Machine learning helps construct diagnostic models for IPF

Researchers in China used machine learning — a type of artificial intelligence in which computers detect patterns in datasets and then make predictions — to create diagnostic and prognostic models for use in idiopathic pulmonary fibrosis (IPF). Using the new models, the team observed gene activity changes suggestive of…